tbuckley/cabot-search huggingface dataset:
Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203
Authors: M. J. Edelman, D. M. Watson, X. Wang, R. A. Kratzke, A. M. Mauer, M. R. Green, E. E. Vokes, S. L. Graziano, G. A. Masters, M. M. Bedor
Journal: Journal of Clinical Oncology (2006)

7025 Background: Increased expression of eicosanoids have been associated with adverse prognosis. Specific inhibitors of key enzymes of two eicosanoid pathways, COX-2 (celecoxib) and 5-LOX (zileuton) have been developed. In vitro, the addition of these inhibitors have demonstrated enhancement of cytotoxic chemotherapy. We hypothesized that the addition of eicosanoid inhibitors to standard chemotherapy of carboplatin (C) and gemcitabine (G) could improve outcome in advanced NSCLC. Methods: Patients (pts) with stage IIIb (pleural effusion)/stage IV NSCLC, PS 0–2, no prior therapy were eligible. All pts received up to six cycles of C AUC 5.5 d1 + G (1000 mg/m2) d1,8. Pts were randomized to three arms: A: Celecoxib (CEL) 400 mg po bid. B: Zileuton (Z) 600 mg qid po, C: CEL and Z at the same doses. CEL and Z were begun on the first day of therapy and continued until progression. In this randomized phase II trial, the objective was to demonstrate a 50% failure free survival (FFS) at 9 months. Serum and tissue samples were required. Results: Between 12/05/03 and 9/30/04, 140 pts were entered and 136 were eligible and treated (A: 44, B: 47, C: 45). M: 86, F: 50; PS 0,1,2 = 38,85,13. Toxicity was primarily hematologic with approximately 70% grade 3/4 toxicity on each arm. Response and survival with 95% CI (see table ). Arm C has superior FFS when compared to combined Arms A+B (p =.054, unstratified log rank test), however, this benefit decreases when adjusted for baseline PS (0 vs, 1,2) and stage (IIIB vs. IV) in a Cox model, p=.15, 2-sided Wald test. There was no difference in terms of OS (p=.96). Serum and tissue were submitted for &gt;90%. Analysis of COX-2 and 5-LOX expression are pending. Conclusions: 1. The combination of C/G + eicosanoid modulators was well tolerated. 2. The trend towards improved FFS in Arm C is intriguing, however, did not achieve the primary endpoint. 3. Correlative studies which may be able to identify pts likely to benefit from this approach are in progress. [Table: see text] [Table: see text]
Increased Expression of Neutrophil and Monocyte Adhesion Molecules LFA-1 and Mac-1 and Their Ligand ICAM-1 and VLA-4 Throughout the Acute Phase of Myocardial Infarction
Authors: Simcha R. Meisel, Hava Shapiro, Judith Radnay, Yoram Neuman, Abdul-Rahim Khaskia, Nachman Gruener, Hana Pauzner, Daniel David
Journal: Journal of the American College of Cardiology (1998)
Abstract 17741: Dehydroepiandrosterone (DHEA) Reverses Pulmonary Hypertension Through Inhibition of the Stat3/Pim1/NFAT Axis
Authors: Jolyane Meloche, Roxane Paulin, Sebastien Bonnet
Journal: Circulation (2010)

Background: Pulmonary Arterial Hypertension (PAH) are obstructive vasculopathy characterized by enhanced pulmonary artery smooth muscle cells (PASMC) proliferation and suppressed apoptosis. We recently described that this phenotype is associated with Signal Transducer and Activator of Transcription3 (STAT3)/ Provirus Integration site for Moloney murine leukemia virus (Pim1)/Nuclear Factor of Activated T-cells (NFAT) axis activation, resulting in proliferation and apoptosis resistance. Dehydroepiandrosterone (DHEA) is a steroid hormone known to reverse vascular remodeling. We hypothesized that DHEA is able to reverse Human Pulmonary Hypertension by inhibiting STAT3/Pim1/NFAT axis. Methods/Results: Using PASMC isolated from patient with PAH (n=3), we demonstrated that DHEA decreases STAT3 activation (Western Blot, luciferase assay). STAT3 inhibition resulted in a significant reduction in Pim1 and NFATc2 expression/activation (qRT-PCR; western blot and ChIP-PCR n=3;p<0.05) and upregulation of BMPR2. STAT3/Pi...
Young's Practice of Urology. Based on a Study of 12,500 Cases.
Authors: Hugh Young, David Melvin Davis, Franklin Paradise Johnson, William P. Didusch
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1871: Atrial Tachyarrhythmias Late After Fontan Operation Are Related to Increase in Mortality and Hospitalization
Authors: Konstantinos Dimopoulos, Georgios Giannakoulas, Serkan Yuksel, Ryo Inuzuka, Antonia Pijuan-Domenech, Wajid Hussain, Edgar Lik Tay, Michael A Gatzoulis, Tom Wong
Journal: Circulation (2009)
The Science of Biology. An Introductory Study.
Authors: George G. Scott
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular Screening in College Athletes
Authors: Jonathan A. Drezner, Jordan M. Prutkin, Kimberly G. Harmon, John W. O’Kane, Hank F. Pelto, Ashwin L. Rao, Jeffrey D. Hassebrock, Bradley J. Petek, Colin Teteak, Miranda Timonen, Monica Zigman, David S. Owens
Journal: Journal of the American College of Cardiology (2015)
A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05–1T trial
Authors: A. Delmer, O. Fitoussi, P. Gaulard, G. Laurent, D. Bordessoule, F. Morschhauser, C. Ferme, H. Tilly, C. Gisselbrecht, B. Coiffier
Journal: Journal of Clinical Oncology (2009)

8554 Background: Patients with peripheral T/NK cell lymphomas (PTCL) still have a dismal prognosis with 5-yr survival less than 30% in most cases. No alternative regimen has been proven superior to CHOP so far. This multicenter phase II study was carried out to assess efficacy and safety of bortezomib in combination with an intensified CHOP-like regimen. Methods: Pts aged 18 to 65 yrs with previously untreated PTCL were planned to receive 4 bi-monthly cycles of ACVBP (doxorubicine 75 mg/m 2 D1, cyclophosphamide 1200 mg/m 2 D1, vindesine 2 mg/m 2 D1 and D5, bleomycine 10 mg D1 and D5 and prednisone D1 to D5) followed by a sequential consolidation consisting of HD methotrexate (2 courses), etoposide + ifosfamide (4 courses) and cytarabine (2 courses) at 2 weeks intervals. Bortezomib 1.5 mg/m 2 was administered at D1 and D5 of each ACVBP cycle, and then at D1, D8 and D15 every 4 weeks during consolidation phase for a total of 20 injections during the whole treatment. Results: 57 eligible pts (M 38, F 19, median age 52.5 yrs) with mostly AITL and PTCL NOS subtypes were enrolled between January 2006 and November 2007; 78% had stage III-IV disease and 53% had aaIPI ≥ 2. Forty six pts (81%) have completed induction treatment with ACVBP and only 28 (49%) the consolidation phase, mainly for disease progression. The CR + CRu rate was 45% after induction and 46% after consolidation. As of November 14 th , 2008, 22 pts (39%) have died, mostly from lymphoma. The median percentage of planned dose of bortezomib received was 98% during ACVBP induction where the vinca alkaloid used was vindesine, and ranged from 90 to 95% during the consolidation courses. The dose intensity of bortezomib was 84.3% during induction, similar to that of doxorubicine and cyclophosphamide. Thrombocytopenia was more pronounced than previously observed with ACVBP alone but no life-threatening hemorrhagic event occurred. Conclusions: The combination of bortezomib with ACVBP is feasible without neurological or platelet unexpected toxicities. The response rate of such a regimen in PTCL does not appear higher than previously observed with ACVBP alone in our historical cohort. No significant financial relationships to disclose.
Immunohistochemistry on bonemarrow paraffin sections for characterization of acute leukemia in an under resourced laboratory
Authors: V. Lakshmidevi, D. S. Madhumathi, T. S. Sundareshan, M. Malathi, L. Appaji, P. P. Bapsy
Journal: Journal of Clinical Oncology (2008)

18032 Background: Kidwai Memorial Institute of Oncology is a cancer centre in India offering subsidized treatment to poor patients. Each year 350+ cases of acute leukemia are characterized by morphology and cytochemistry of bone marrow aspirate (BMA) smears. Conventional cytogenetics is available. Flow cytometry, (FC) available outside the centre is beyond the financial reach of most patients. In some cases, BMA is difficult to obtain because of a packed marrow/fibrosis. We attempted immunohistochemistry (IHC) on bone marrow biopsy (BMB) paraffin sections of 30 cases with a limited panel of antibodies. Methods: 30 cases were chosen to diagnose carcinoma/leukemia, lineage assignment ALL/AML M0 or to categorise ALL into T and B cell types. 6 available markers were used: MPO, Tdt, CD 3, CD 20, CD 68 and F8RA. The BMBs were fixed in 10% formalin, decalcified in 10% EDTA and routinely processed. A manual streptavidin biotin technique was used, with appropriate positive and negative controls. The slides were reviewed by 3 hematopathologists. 20% of the blasts taking the stain was considered positive. FC findings (4 cases), and karyotype (19 cases) were tabulated. Results: In 3 cases, morphology and IHC were suggestive of AML. In 15 cases, morphology was inconclusive. After IHC, a diagnosis of ALL was made in 10 cases, AML in 3 cases, including a child with extensive myelofibrosis. 2 cases of mixed lineage leukemia (MLL/ALL) were diagnosed. 11 cases of ALL were classified as T in 7 cases, and pre B in 4 cases. 5/7 T ALL cases had massive mediastinal nodes. In 1 case, cytokeratin and CD 45 were run in addition. Burkitt’s leukemia was diagnosed, confirmed by a complex karyotype including t(8:14)(q24;q32)10/19 cases had a normal karyotype. The rest showed a good correlation. Conclusions: 1. A limited panel of Tdt, MPO, CD 20 and CD 3 provide good information. 2. Our patients paid Rs 200 per marker, FC costs Rs 1000. 3. IHC can differentiate carcinoma from leukemia, diagnose ALL, differentiate T and B ALL, and help in the diagnosis of MLL. 4. Background staining by MPO hinders the diagnosis of AML. Therefore, IHC on BMB sections is valuable in the categorization of acute leukemia, particularly in under resourced laboratories. No significant financial relationships to disclose.
Abstract 9123: Utilization of TIMI Risk Index in Determining the Need of Admission to Coronary Care Unit for Acute ST Elevation Myocardial Infarction Patient After Successful Primary Percutaneous Coronary Intervention: Single Centre Study
Authors: Vern Hsen Tan, Chong Hiok Tan, Jeremy Chow, Kok Soon Tan, Jayaram Lingamanaicker, Victor Lim, Khim Leng Tong, Gerard Leong, Hwa Wooi Gan, Sea Hing Ong, Yew Seong Goh, Colin Yeo, Ping Ping Goh
Journal: Circulation (2011)

Introduction: With the ever-increasing number of acutely ill patients with cardiac disease that need intensive monitoring and limited resources in coronary care unit (CCU), there is a need to ensure appropriate admission to CCU. TIMI risk index (TRI) was a robust predictor (for STEMI patients on first arrival in hospital) and high discriminatory capacity of in-hospital events. TRI was divided into five risk groups with the higher the index score, the higher the mortality. We attempt to study TIMI risk index {TRI = [heart rate X (age/10)2]/systolic blood pressure} in determining the need of admission to CCU for STEMI patient after successful primary percutaneous coronary intervention (PPCI). Methods: This was a retrospective study over 12 months period. Inclusion criterias including patient presented with STEMI at emergency department and underwent successful PPCI which defined as achieving TIMI 3 flow. Exclusion criterias include no documentation of blood pressure and/or heart rate at presentation at emergency department. Study end point was in-hospital major adverse cardiovascular events (MACE) that include all cause death including cardiac death, target lesion revascularization, recurrent myocardial infarction, stroke, in-stent thrombosis. Results: A total of 275 patients had STEMI and underwent PPCI. 16 patients were excluded (13 patients did not have heart rate and/or blood pressure documented at presentation and 3 patients had unsuccessful PPCI). Majority was male (85.3%) and had anterior STEMI (51.0%). In the first two groups (risk group 1 and risk group 2), there was no in-hospital MACE as compare to the last two groups (risk group 4 and risk group 5), in which the in-hospital MACE was &gt;10% (12.2% and 17.0% respectively, p=0.001). The in-hospital mortality was high in the last two groups (9.8% and 13.2% respectively) as compare to no in-hospital mortality in the first two groups, p=0.004. Non of the patients in risk group 1 and 2 required intra-aortic balloon counterpulsation. Conclusions: Patients presented with acute STEMI with TRI &lt;17.5 at presentation and underwent successful PPCI for STEMI did not encounter any in-hospital MACE and may probably benefit from observation in step-down unit and the implication may result in substantial cost savings.
Abstract 14530: Long-Term Risk Reduction of Major Amputation in Patients with Critical Limb Ischemia by Autologus Bone-Marrow Cell Implantation
Authors: Naomi Idei, Yukihito Higashi, Noritaka Fujimura, Shinsuke Mikami, Tatsuya Maruhashi, Yumiko Iwamoto, Takaki Hata, Yuichi Fujii, Junko Soga, Takayuki Hidaka, Kenji Nishioka, Kensuke Noma, Yasuki Kihara
Journal: Circulation (2011)

Background: Autologous bone-marrow mononuclear cell (BM-MNC) implantation increases collateral vessel formation and improves ischemic symptoms in patients with critical limb ischemia. However, ther...
Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor
Authors: S. Mishra, D. Bedja, C. Amuzie, C.A. Foss, M.G. Pomper, R. Bhattacharya, K.J. Yarema, S. Chatterjee
Journal: Biomaterials (2015)
Measuring success after radical cystectomy: Feasibility of a novel composite endpoint ("poor recovery") to quantify outcomes after surgery.
Authors: Erika L. Wood, Janet E. Baack Kukreja, Sima P. Porten, Raphael Ezeagu, Wei Qiao, Neema Navai, Ashish M. Kamat, Colin P. N. Dinney, Jay Bakul Shah
Journal: Journal of Clinical Oncology (2015)

357 Background: Given the predilection of invasive bladder cancer toward older sicker patients and the complexity of radical cystectomy (RC), it is not surprising many patients experience prolonged, difficult recoveries. There is growing interest in identifying ways to improve recovery after RC. To date, studies have focused on inpatient length of stay (LOS) as the primary measure of recovery improvement efforts. Given that many patients suffer complications after discharge and require hospital readmission, inpatient LOS may not be the most useful measure. We propose a novel endpoint – “Poor Recovery” – as a more encompassing measure of outcomes after RC. Methods: A comprehensive perioperative multidisciplinary algorithm known as the Optimized Surgical Journey (OSJ) has been in development at our institution over the last 18 months. We selected 50 patients who underwent RC with the OSJ algorithm and 50 patients who underwent RC with usual care during the same time period. Poor Recovery was defined by inpatient LOS &gt; 7 days or hospital readmission within 30 days. Statistical analyses included Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables. Results: Patients in the OSJ group had significantly shorter times to first flatus, bowel movement, ambulation, and resumption of regular diet (Table). There were no differences between the groups in operative time, blood loss, opioid use, or rate of ICU admission. Mean LOS was significantly shorter in the OSJ group (5.6 and 8.5 days, p&lt;0.01). Poor Recovery was experienced by 18% of the patients in the OSJ group and 70% of the patients in the non-OSJ group (p&lt;0.01). Conclusions: We define a novel composite endpoint, Poor Recovery, that can help measure outcomes after RC. For future prospective studies of accelerated recovery pathways, the poor recovery endpoint may be a useful metric by which to determine the efficacy of various interventions. [Table: see text]
Enlargement of the Prostate. Its Treatment and Radical Cure
Authors: C. Mansell Moullin
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mitral valve prolapse syndrome in agoraphobic patients
Authors: J S Kantor, C M Zitrin, S M Zeldis
Journal: American Journal of Psychiatry (1980)

Twenty-five agoraphobic women were compared with 23 controls for the presence of mitral valve prolapse syndrome (MVP). All subjects underwent cardiac examination, electrocardiography, phonocardiography, and echocardiography. Eleven of the agoraphobic patients had MVP; 5 had echo findings alone, 3 had both auscultory and echo findings, and 3 had auscultory findings alone. Two controls had evidence of MVP, both with echo findings alone. Echo chamber size and wall motion were similar in both groups. One patient had inferior T wave changes on ECG while all controls had normal tracings. The authors conclude that a significant number of agoraphobic patients have MVP and discuss the thoretical and clinical implications of this association.
Sports Medicine for Trainers.
Authors: Laurence Englemohr Morehouse, Philip J. Rasch
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Surgery and Pathology of the Thyroid and Parathyroid Glands.
Authors: Ralph L. Thompson, Albert J. Ochsner
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal